Synlogic, Inc. (SYBX) News
Filter SYBX News Items
SYBX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest SYBX News From Around the Web
Below are the latest news stories about SYNLOGIC INC that investors may wish to consider to help them evaluate SYBX as an investment opportunity.
Synlogic Third Quarter 2024 Earnings: US$0.01 loss per share (vs US$2.57 loss in 3Q 2023)Synlogic ( NASDAQ:SYBX ) Third Quarter 2024 Results Key Financial Results Net loss: US$117.0k (loss narrowed by 99... |
Synlogic Reports Third Quarter 2024 Financial ResultsWINCHESTER, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the third quarter 2024 and provided a corporate update. As previously announced, the Company retained Lucid Capital Markets, LLC to act as its financial advisor to explore and evaluate strategic options for maximizing shareholder value. Potential strategic alternatives that may |
Otsuka snaps up Jnana with its phenylketonuria drug for $800mThe acquisition is expected to conclude in Q3 this year and will see Otsuka adding Jnana’s Phase I/II phenylketonuria therapy to its rare disease portfolio. |
Synlogic Reports Second Quarter 2024 Financial ResultsWINCHESTER, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the second quarter 2024 and provided a corporate update. In March 2024, the Company retained Lucid Capital Markets, LLC to act as its financial advisor to explore and evaluate strategic options for maximizing shareholder value. Potential strategic alternatives that may be explor |
The Summer Stock Exodus: 3 Companies to Ditch Before the Heat Hits“Sell in May and go away” is a common adage in investing. It’s based on the historical pattern of stocks underperforming from May to October when investors tend to stay on the sidelines. While timing the market is sketchy work at best, following the herd might be the best option for some investors. All that’s left is figuring out if you’re holding prime stocks to sell. So, I’ve developed a list of companies that might get the short stick in May based on these criteria. Trade above their mean tar |
Synlogic Reports First Quarter 2024 Financial ResultsCAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the first quarter 2024 and provided a corporate update. In March 2024, the Company retained Lucid Capital Markets, LLC to act as its financial advisor to explore and evaluate strategic options for maximizing shareholder value. Potential strategic alternatives that may be explored |
We Think Synlogic (NASDAQ:SYBX) Needs To Drive Business Growth CarefullyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Synlogic, Inc. (SYBX) Reports Q4 Loss, Tops Revenue EstimatesSynlogic, Inc. (SYBX) delivered earnings and revenue surprises of -54.05% and 2.37%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock? |
Synlogic Reports Fourth Quarter and Full Year 2023 Financial ResultsCAMBRIDGE, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the fourth quarter and full year ending December 31, 2023. The Company recently announced the decision to discontinue Synpheny-3, its pivotal study of labafenogene marselecobac (SYNB1934) in phenylketonuria (PKU) and evaluate strategic options for the Company. Fourth Quarter 202 |
Synlogic Adopts Limited Duration Stockholders Rights PlanEngages Ladenburg Thalmann as financial advisor to assist with previously announced strategic review processCAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today announced that its Board of Directors (the “Board”) has approved the adoption of a limited duration shareholder rights plan (the "Rights Plan") and authorized a dividend distribution of one right ("Right |